Clinical and Experimental Dermatology最新文献

{"title":"Consenting for Mortality Risk in Dermatological Surgery: Is It Necessary?","authors":"John H Ye, Lydia Partridge, Luke Brindley, David Veitch, Aaron Wernham","doi":"10.1093/ced/llag421","DOIUrl":"https://doi.org/10.1093/ced/llag421","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149079695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bridging gaps in hidradenitis suppurativa care in Scotland: a comment on 'Secondary care management of patients with hidradenitis suppurativa in the United Kingdom and Ireland: a survey of current practice'.","authors":"Dhanya Kuladeva, Vivienne Nguyen, Hazel Rooney, Alison Honan","doi":"10.1093/ced/llag211","DOIUrl":"10.1093/ced/llag211","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1892-1893"},"PeriodicalIF":2.8,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147970986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Purpura fulminans-like presentation of Lucio leprosy: a case report.","authors":"Archita Bhattacharya, Bikash Kar, Manoj Nayak, Nibedita Dixit","doi":"10.1093/ced/llag236","DOIUrl":"10.1093/ced/llag236","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1919-1922"},"PeriodicalIF":2.8,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148155563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tumour-field-predominant bullous pemphigoid in a patient with metastatic melanoma.","authors":"Alessia Caligiure, Endrio Kaja, Alba Guglielmo, Arianna De Martino, Sebastiano Posenato, Lucia Mantovani, Aikaterini Kalpaktsoglou, Roberta Gafà, Massimo Guidoboni, Alessandro Borghi","doi":"10.1093/ced/llag243","DOIUrl":"10.1093/ced/llag243","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1923-1925"},"PeriodicalIF":2.8,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148204267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on 'Risk of inflammatory dermatoses following COVID-19 infection: a cohort study of 204 241 patients': considerations regarding causal inference.","authors":"Xue Xu, Rongying Wang, Qianqian Zhang, Yulin Zou","doi":"10.1093/ced/llag245","DOIUrl":"10.1093/ced/llag245","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1931-1932"},"PeriodicalIF":2.8,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148210290","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment of severe refractory chronic actinic dermatitis with upadacitinib: a case series of four patients.","authors":"Nidia Planella-Fontanillas, Jorge Magdaleno-Tapial, Vicente Expósito-Serrano, Marta Ferran-Farrés, Amparo Pérez Ferriols, Nasser Mohammad Porras, Ana M Giménez-Arnau, Fernando Gallardo, Ramon M Pujol","doi":"10.1093/ced/llag160","DOIUrl":"10.1093/ced/llag160","url":null,"abstract":"<p><p>Chronic actinic dermatitis (CAD) is a rare immune-mediated photodermatosis that may be severe, generalized and refractory to conventional therapies. We describe four men (aged 44-65 years) with long-standing severe CAD, which was unresponsive to multiple systemic treatments, including immunosuppressants, dupilumab and tofacitinib. All patients presented with marked photosensitivity and two had erythroderma. Extensive investigation excluded cutaneous T-cell lymphoma. Photobiological testing demonstrated reduced minimal erythema doses to ultraviolet B adjusted for phototype, supporting the diagnosis of CAD. Upadacitinib (15-30 mg once daily) was initiated off-label. Clinical improvement occurred within 4 weeks, with complete remission achieved between 4 and 8 weeks in all patients. Remission was sustained for up to 12 months of follow-up. Treatment was well tolerated, with only mild acneiform eruption and transient hypertriglyceridaemia in one patient. These findings suggest that selective Janus kinase 1 inhibition may represent a therapeutic option in severe treatment-refractory CAD.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1881-1886"},"PeriodicalIF":2.8,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147670675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous infections and infestations.","authors":"Varun H, Adarshlata Singh, Bhushan Madke, Vangala Naga Nitya","doi":"10.1093/ced/llag172","DOIUrl":"10.1093/ced/llag172","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1935-1936"},"PeriodicalIF":2.8,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147697778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Depigmented facial and neck patches following melanotan use in a patient with atopic dermatitis and alopecia areata.","authors":"Adaku Ume, Shae Chambers, Scott Worswick","doi":"10.1093/ced/llag221","DOIUrl":"10.1093/ced/llag221","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1971-1974"},"PeriodicalIF":2.8,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148052928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of early incomplete sections on Mohs micrographic surgery margin assessment.","authors":"William Phillips, Michael J Davis, Megan H Trager, Cristian Navarrete-Dechent, Anthony Rossi, Erica Lee, Kishwer Nehal","doi":"10.1093/ced/llag196","DOIUrl":"10.1093/ced/llag196","url":null,"abstract":"<p><p>Variations exist in the evaluation of complete circumferential and deep margin assessment among Mohs surgeons, including section spacing, physical placement of the first section on the slide and acceptable tumour-free margins. The impact of early incomplete sections (EIS) on margin interpretation has not been systematically studied. We evaluated how inclusion of EIS affected the interpretation of tumour status during Mohs micrographic surgery. We retrospectively analysed 500 basal cell carcinoma (BCC) Mohs pieces with EIS and prospectively evaluated 250 serially step-sectioned BCC pieces. In the retrospective cohort, inclusion of EIS reduced interpreted positivity from 47.2% to 41.2%, reclassifying 12.7% of initially positive pieces as negative. Prospectively, EIS reduced positivity from 35.6% to 27.2%. Incorporation of EIS may reduce false positive margin interpretations in Mohs micrographic surgery and could potentially decrease unnecessary additional stages, depending on surgeon margin thresholds and cutting depth. The clinical application is nuanced and should take into account patient and tumour factors, as determined by the Mohs surgeon.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1887-1891"},"PeriodicalIF":2.8,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13614101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147811988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of oral minocycline hydrochloride 40 mg extended-release capsules (DFD-29) versus doxycycline in rosacea: a systematic review and meta-analysis.","authors":"Laura Ghanem, Cristina Sicorschi Gutu, Daniela Lucía Mendoza-Millán, Carlos Alberto Monteiro Leitão Neto, Martin Cevallos-Cueva, Devanie Martani, Victor Barreiros Pungirum, Camila Almeida Sardinha, Peter Chien","doi":"10.1093/ced/llag118","DOIUrl":"10.1093/ced/llag118","url":null,"abstract":"<p><strong>Background: </strong>Rosacea is a chronic skin disorder characterized by facial erythema, telangiectasias, papules and pustules. Guidelines recommend subantimicrobial doses of drugs such as doxycycline 40 mg. In patients with persistent symptoms, evaluating the efficacy and safety of subantimicrobial doses of minocycline may expand treatment options.</p><p><strong>Objectives: </strong>To evaluate minocycline hydrochloride 40 mg extended-release capsules (formerly known as and hereafter referred to as DFD-29) as a low-dose tetracycline alternative to treat rosacea.</p><p><strong>Methods: </strong>Our analysis included data from three randomized controlled trials sourced from the PubMed, Embase and Cochrane databases to compare Investigator Global Assessment treatment success (IGA-TS) scores, reduction in inflammatory lesion counts, treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients using DFD-29 vs. modified-release doxycycline. Statistical analyses were conducted using RStudio.</p><p><strong>Results: </strong>In a pooled analysis of 643 patients, DFD-29 significantly increased the likelihood of achieving a successful IGA-TS score compared with doxycycline [odds ratio (OR) 2.51, 95% confidence interval (CI) 1.80-3.49; P < 0.001; I2 = 0%]. The DFD-29 40 mg group had significantly greater reductions in IGA-TS scores compared with the DFD-29 20 mg group (P = 0.02). The DFD-29 40 mg group also exhibited a significantly greater reduction in inflammatory lesion counts than the doxycycline group (mean difference -4.56, 95% CI -6.18 to -2.93; P < 0.001), whereas the DFD-29 20 mg group showed no significant reduction. There were no significant differences in TEAEs across groups (OR 0.96, 95% CI 0.55-1.66; P = 0.87; I2 = 0%), with just one SAE (atrial fibrillation) reported with DFD-29.</p><p><strong>Conclusions: </strong>Our meta-analysis showed that DFD-29 at 40 mg daily is a superior, well-tolerated alternative to modified-release doxycycline for moderate-to-severe rosacea.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":"1803-1811"},"PeriodicalIF":2.8,"publicationDate":"2026-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147389580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}